Open questions for Alzheimer's disease immunotherapy

Alzheimer's Research and Therapy

Volumn 6, Issue 1, 2014, Pages

  Golde, Todd E ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; EPITOPE; TAU PROTEIN;

ALZHEIMER DISEASE; BINDING AFFINITY; BRAIN; CLINICAL EFFECTIVENESS; COST BENEFIT ANALYSIS; DRUG MECHANISM; IMMUNOTHERAPY; NONHUMAN; OPTIMISM; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW;

EID: 84891864287     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt233     Document Type: Review

References (56)

1. Treating Alzheimer's disease with monoclonal antibodies; current status and outlook to the future. ND Prins, P Scheltens, Alzheimers Res Ther 2013 5 56 10.1186/alzrt220 24216217
2. Quantitative and mechanistic studies of abeta immunotherapy. TE Golde, P Das, Y Levites, CNS Neurol Disord Drug Targets 2009 8 31 49 10.2174/ 187152709787601830 19275635
3. Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. Y Levites, LA Smithson, RW Price, RS Dakin, B Yuan, MR Sierks, J Kim, E McGowan, DK Reed, TL Rosenberry, P Das, TE Golde, FASEB J 2006 20 2576 2578 10.1096/fj.06-6463fje 17068112 (Pubitemid 44953785)
4. A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo. JK Atwal, Y Chen, C Chiu, DL Mortensen, WJ Meilandt, Y Liu, CE Heise, K Hoyte, W Luk, Y Lu, K Peng, P Wu, L Rouge, Y Zhang, RA Lazarus, K Scearce-Levie, W Wang, Y Wu, M Tessier-Lavigne, RJ Watts, Sci Transl Med 2011 3 84ra43 10.1126/scitranslmed.3002254 21613622
5. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. YJ Yu, Y Zhang, M Kenrick, K Hoyte, W Luk, Y Lu, J Atwal, JM Elliott, S Prabhu, RJ Watts, MS Dennis, Sci Transl Med 2011 3 84ra44 10.1126/scitranslmed.3002230 21613623
6. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. RB DeMattos, KR Bales, DJ Cummins, SM Paul, DM Holtzman, Science 2002 295 2264 2267 10.1126/science.1067568 11910111 (Pubitemid 34258840)
7. Delivery of peptides and proteins through the blood-brain barrier. U Bickel, T Yoshikawa, WM Pardridge, Adv Drug Deliv Rev 2001 46 247 279 10.1016/S0169-409X(00)00139-3 11259843
8. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. HJ Lee, B Engelhardt, J Lesley, U Bickel, WM Pardridge, J Pharmacol Exp Ther 2000 292 1048 1052 10688622 (Pubitemid 30136600)
9. Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice. DR Thakker, MR Weatherspoon, J Harrison, TE Keene, DS Lane, WF Kaemmerer, GR Stewart, LL Shafer, Proc Natl Acad Sci U S A 2009 106 4501 4506 10.1073/pnas.0813404106 19246392
10. Transgenic expression of beta1 antibody in brain neurons impairs age-dependent amyloid deposition in APP23 mice. P Paganetti, J Reichwald, D Bleckmann, D Abramowski, D Ammaturo, C Barske, S Danner, M Molinari, M Müller, S Papin, S Rabe, P Schmid, M Staufenbiel, Neurobiol Aging 2013 34 2866 2878 10.1016/j.neurobiolaging.2013.06.013 23870837
11. NMDA receptor antibody encephalitis. SR Irani, A Vincent, Curr Neurol Neurosci Rep 2011 11 298 304 10.1007/s11910-011-0186-y 21331529
12. Movement disorders in paraneoplastic and autoimmune disease. J Panzer, J Dalmau, Curr Opin Neurol 2011 24 346 353 10.1097/WCO.0b013e328347b307 21577108
13. Physiology of blood-brain interfaces in relation to brain disposition of small compounds and macromolecules. N Strazielle, JF Ghersi-Egea, Mol Pharm 2013 10 1473 1491 10.1021/mp300518e 23298398
14. Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. Y Zhang, WM Pardridge, J Neuroimmunol 2001 114 168 172 10.1016/S0165-5728(01)00242-9 11240028 (Pubitemid 32184738)
15. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. R Deane, A Sagare, K Hamm, M Parisi, B LaRue, H Guo, Z Wu, DM Holtzman, BV Zlokovic, J Neurosci 2005 25 11495 11503 10.1523/JNEUROSCI.3697-05.2005 16354907 (Pubitemid 43102486)
16. Investigation of the role of FcgammaR and FcRn in mAb distribution to the brain. L Abuqayyas, JP Balthasar, Mol Pharm 2013 10 1505 1513 10.1021/mp300214k 22838637
17. Brain-wide pathway for waste clearance captured by contrast-enhanced MRI. JJ Iliff, H Lee, M Yu, T Feng, J Logan, M Nedergaard, H Benveniste, J Clin Invest 2013 123 1299 1309 10.1172/JCI67677 23434588
18. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. JJ Iliff, M Wang, Y Liao, BA Plogg, W Peng, GA Gundersen, H Benveniste, GE Vates, R Deane, SA Goldman, EA Nagelhus, M Nedergaard, Sci Transl Med 2012 4 147ra111 10.1126/scitranslmed.3003748 22896675
19. Evaluating glymphatic pathway function utilizing clinically relevant intrathecal infusion of CSF tracer. L Yang, BT Kress, HJ Weber, M Thiyagarajan, B Wang, R Deane, H Benveniste, JJ Iliff, M Nedergaard, J Transl Med 2013 11 107 10.1186/1479-5876-11-107 23635358
20. Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. RO Weller, SD Preston, M Subash, RO Carare, Alzheimers Res Ther 2009 1 6 10.1186/alzrt6 19822028
21. Developing therapeutic antibodies for neurodegenerative disease. YJ Yu, RJ Watts, Neurotherapeutics 2013 10 459 472 10.1007/s13311-013-0187-4 23549647
22. Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse. P Seubert, R Barbour, K Khan, R Motter, P Tang, D Kholodenko, K Kling, D Schenk, K Johnson-Wood, S Schroeter, D Gill, JS Jacobsen, M Pangalos, G Basi, D Games, Neurodegener Dis 2008 5 65 71 10.1159/000112834 18182780
23. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. JC Dodart, KR Bales, KS Gannon, SJ Greene, RB DeMattos, C Mathis, CA DeLong, S Wu, X Wu, DM Holtzman, SM Paul, Nat Neurosci 2002 5 452 457 11941374 (Pubitemid 34454251)
24. Pyroglutamate amyloid-beta (Abeta): a hatchet man in Alzheimer disease. S Jawhar, O Wirths, TA Bayer, J Biol Chem 2011 286 38825 38832 10.1074/jbc.R111.288308 21965666
25. Nitration of tyrosine 10 critically enhances amyloid beta aggregation and plaque formation. MP Kummer, M Hermes, A Delekarte, T Hammerschmidt, S Kumar, D Terwel, J Walter, HC Pape, S König, S Roeber, F Jessen, T Klockgether, M Korte, MT Heneka, Neuron 2011 71 833 844 10.1016/j.neuron.2011.07.001 21903077
26. Pyroglutamate-3 amyloid-beta deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models. JL Frost, KX Le, H Cynis, E Ekpo, M Kleinschmidt, RM Palmour, FR Ervin, S Snigdha, CW Cotman, TC Saido, RJ Vassar, P St George-Hyslop, T Ikezu, S Schilling, HU Demuth, CA Lemere, Am J Pathol 2013 183 369 381 10.1016/j.ajpath.2013.05.005 23747948
27. A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer's disease mice. RB Demattos, J Lu, Y Tang, MM Racke, CA Delong, JA Tzaferis, JT Hole, BM Forster, PC McDonnell, F Liu, RD Kinley, WH Jordan, ML Hutton, Neuron 2012 76 908 920 10.1016/j.neuron.2012.10.029 23217740
28. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. RB DeMattos, KR Bales, DJ Cummins, JC Dodart, SM Paul, DM Holtzman, Proc Natl Acad Sci U S A 2001 98 8850 8855 10.1073/pnas.151261398 11438712 (Pubitemid 32678116)
29. Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. Y Levites, K Jansen, LA Smithson, R Dakin, VM Holloway, P Das, TE Golde, J Neurosci 2006 26 11923 11928 10.1523/JNEUROSCI.2795-06.2006 17108166 (Pubitemid 44772103)
30. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. P Das, V Howard, N Loosbrock, D Dickson, MP Murphy, TE Golde, J Neurosci 2003 23 8532 8538 13679422 (Pubitemid 37158753)
31. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. BJ Bacskai, ST Kajdasz, ME McLellan, D Games, P Seubert, D Schenk, BT Hyman, J Neurosci 2002 22 7873 7878 12223540 (Pubitemid 35379092)
32. An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. O Adolfsson, M Pihlgren, N Toni, Y Varisco, AL Buccarello, K Antoniello, S Lohmann, K Piorkowska, V Gafner, JK Atwal, J Maloney, M Chen, A Gogineni, RM Weimer, DL Mortensen, M Friesenhahn, C Ho, R Paul, A Pfeifer, A Muhs, RJ Watts, J Neurosci 2012 32 9677 9689 10.1523/JNEUROSCI.4742-11.2012 22787053
33. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. S Ostrowitzki, D Deptula, L Thurfjell, F Barkhof, B Bohrmann, DJ Brooks, WE Klunk, E Ashford, K Yoo, ZX Xu, H Loetscher, L Santarelli, Arch Neurol 2012 69 198 207 10.1001/archneurol.2011.1538 21987394
34. Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. B Bohrmann, K Baumann, J Benz, F Gerber, W Huber, F Knoflach, J Messer, K Oroszlan, R Rauchenberger, WF Richter, C Rothe, M Urban, M Bardroff, M Winter, C Nordstedt, H Loetscher, J Alzheimers Dis 2012 28 49 69 21955818
35. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. DM Wilcock, J Alamed, PE Gottschall, J Grimm, A Rosenthal, J Pons, V Ronan, K Symmonds, MN Gordon, D Morgan, J Neurosci 2006 26 5340 5346 10.1523/JNEUROSCI.0695-06.2006 16707786 (Pubitemid 44318386)
36. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. RA Sperling, CR Jack Jr, SE Black, MP Frosch, SM Greenberg, BT Hyman, P Scheltens, MC Carrillo, W Thies, MM Bednar, RS Black, HR Brashear, M Grundman, ER Siemers, HH Feldman, RJ Schindler, Alzheimers Dement 2011 7 367 385 10.1016/j.jalz.2011.05.2351 21784348
37. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. R Sperling, S Salloway, DJ Brooks, D Tampieri, J Barakos, NC Fox, M Raskind, M Sabbagh, LS Honig, AP Porsteinsson, I Lieberburg, HM Arrighi, KA Morris, Y Lu, E Liu, KM Gregg, HR Brashear, GG Kinney, R Black, M Grundman, Lancet Neurol 2012 11 241 249 10.1016/S1474-4422(12)70015-7 22305802
38. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. B Winblad, N Andreasen, L Minthon, A Floesser, G Imbert, T Dumortier, RP Maguire, K Blennow, J Lundmark, M Staufenbiel, JM Orgogozo, A Graf, Lancet Neurol 2012 11 597 604 10.1016/S1474-4422(12)70140-0 22677258
39. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. S Gilman, M Koller, RS Black, L Jenkins, SG Griffith, NC Fox, L Eisner, L Kirby, MB Rovira, F Forette, JM Orgogozo, AN1792(QS-21)-201 Study Team, Neurology 2005 64 1553 1562 10.1212/01.WNL.0000159740.16984.3C 15883316 (Pubitemid 40617691)
40. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. JM Orgogozo, S Gilman, JF Dartigues, B Laurent, M Puel, LC Kirby, P Jouanny, B Dubois, L Eisner, S Flitman, BF Michel, M Boada, A Frank, C Hock, Neurology 2003 61 46 54 10.1212/01.WNL.0000073623.84147.A8 12847155 (Pubitemid 36818745)
41. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. C Holmes, D Boche, D Wilkinson, G Yadegarfar, V Hopkins, A Bayer, RW Jones, R Bullock, S Love, JW Neal, E Zotova, JA Nicoll, Lancet 2008 372 216 223 10.1016/S0140-6736(08)61075-2 18640458 (Pubitemid 351978111)
42. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease. D Boche, J Donald, S Love, S Harris, JW Neal, C Holmes, JA Nicoll, Acta Neuropathol 2010 120 13 20 10.1007/s00401-010-0705-y 20532897
43. Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. EM Sigurdsson, J Alzheimers Dis 2008 15 157 168 18953105
44. Immunotherapy for tauopathies. J Gu, EM Sigurdsson, J Mol Neurosci 2011 45 690 695 10.1007/s12031-011-9576-5 21739165
45. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. K Yamada, JR Cirrito, FR Stewart, H Jiang, MB Finn, BB Holmes, LI Binder, EM Mandelkow, MI Diamond, VM Lee, DM Holtzman, J Neurosci 2011 31 13110 13117 10.1523/JNEUROSCI.2569-11.2011 21917794
46. Trans-synaptic spread of tau pathology in vivo. L Liu, V Drouet, JW Wu, MP Witter, SA Small, C Clelland, K Duff, PLoS One 2012 7 31302 10.1371/journal.pone.0031302 22312444
47. Propagation of tau pathology in a model of early Alzheimer's disease. A de Calignon, M Polydoro, M Suárez-Calvet, C William, DH Adamowicz, KJ Kopeikina, R Pitstick, N Sahara, KH Ashe, GA Carlson, TL Spires-Jones, BT Hyman, Neuron 2012 73 685 697 10.1016/j.neuron.2011.11.033 22365544
48. Anti-Tau antibodies that block Tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. K Yanamandra, N Kfoury, H Jiang, TE Mahan, S Ma, SE Maloney, DF Wozniak, MI Diamond, DM Holtzman, Neuron 2013 80 402 414 10.1016/j.neuron.2013.07.046 24075978
49. Immunoglobulin G Fc receptor deficiency prevents Alzheimer-like pathology and cognitive impairment in mice. P Fernandez-Vizarra, O Lopez-Franco, B Mallavia, A Higuera-Matas, V Lopez-Parra, G Ortiz-Munoz, E Ambrosio, J Egido, OF Almeida, C Gomez-Guerrero, Brain 2012 135 2826 2837 10.1093/brain/aws195 22961553
50. Autoreactive-Abeta antibodies promote APP beta-secretase processing. J Deng, H Hou, B Giunta, T Mori, YJ Wang, F Fernandez, S Weggen, W Araki, D Obregon, J Tan, J Neurochem 2012 120 732 740 10.1111/j.1471-4159.2011.07629.x 22188568
51. Two novel tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce tau pathology. J Gu, EE Congdon, EM Sigurdsson, J Biol Chem 2013 [epub ahead of print]
52. Intracellular antibody-mediated immunity and the role of TRIM21. WA McEwan, DL Mallery, DA Rhodes, J Trowsdale, LC James, Bioessays 2011 33 803 809 10.1002/bies.201100093 22006823
53. Anti-abeta therapeutics in Alzheimer's disease: the need for a paradigm shift. TE Golde, LS Schneider, EH Koo, Neuron 2011 69 203 213 10.1016/j.neuron.2011.01.002 21262461
54. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. JO Rinne, DJ Brooks, MN Rossor, NC Fox, R Bullock, WE Klunk, CA Mathis, K Blennow, J Barakos, AA Okello, S Rodriguez Martinez de Liano, E Liu, M Koller, KM Gregg, D Schenk, R Black, M Grundman, Lancet Neurol 2010 9 363 372 10.1016/S1474-4422(10)70043-0 20189881
55. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. D Schenk, R Barbour, W Dunn, G Gordon, H Grajeda, T Guido, K Hu, J Huang, K Johnson-Wood, K Khan, D Kholodenko, M Lee, Z Liao, I Lieberburg, R Motter, L Mutter, F Soriano, G Shopp, N Vasquez, C Vandevert, S Walker, M Wogulis, T Yednock, D Games, P Seubert, Nature 1999 400 173 177 10.1038/22124 10408445 (Pubitemid 29327547)
56. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. F Bard, C Cannon, R Barbour, RL Burke, D Games, H Grajeda, T Guido, K Hu, J Huang, K Johnson-Wood, K Khan, D Kholodenko, M Lee, I Lieberburg, R Motter, M Nguyen, F Soriano, N Vasquez, K Weiss, B Welch, P Seubert, D Schenk, T Yednock, Nat Med 2000 6 916 919 10.1038/78682 10932230 (Pubitemid 30644751)